The invention discloses an application of
ceritinib in preparation of a
medicine for treating
echinococcosis. The
ceritinib also comprises a pharmaceutically acceptable salt or a
hydrate of the salt, and a pharmaceutical composition containing pharmaceutically acceptable auxiliary materials. The invention accidentally discovers that the
ceritinib has a remarkable effect of killing protoscolex
in vitro. Experimental results show that when the action concentration of
albendazole is 80 [mu] M, the fatality rate of
albendazole to protoscolex is only 2.5% + / -0.5%, while when the action concentration of ceritinib is 10 [mu] M, the fatality rate of ceritinib to protoscolex can reach 16.00% + / -2.75%, and when the action concentration of ceritinib is 25-80 [mu] M, the fatality rate of ceritinib to protoscolex can reach 100%; microscopic experiments show that when the acting concentration of the ceritinib is 60 mu M, the protoscolex can be completely killed within 8 hours. Therefore, compared with
albendazole for clinically assisting in treating the
echinococcosis, the ceritinib has the advantages that the effect of killing protoscolex
in vitro is more remarkable, the dosage is smaller, the safety is higher, the effect is quicker, and a new
drug choice is provided for treating the
echinococcosis.